Cerebrolysin ®
Cerebrolysin ® is a multi-modal neuropeptide drug with a fast onset of action that helps to regain and maintain the independence of patients suffering from stroke, TBI, dementia and cognitive impairment.
Please consult physician advice for further information.
Safety
Cerebrolysin® is safe and well tolerated! The experience with Cerebrolysin® during many years of clinical application, the information from post-marketing surveillance studies, the safety data from double-blind, placebo-controlled clinical trials and EVER’s pharmacovigilance database demonstrate the excellent clinical safety profile of Cerebrolysin®.
According to EMA classification (European Medicines Agency), Cerebrolysin® is in the SAFE category. In general, reported adverse drug reactions are transient and mild in intensity.
Treating cognitive decline after critical illnesses - A call to action
Brainin, Ely and Bayley will discuss that cognitive decline after stroke, TBI, a COVID infection or delirium deserves much more attention in the minds of physicians worldwide. They will also convincingly point out that such treatment has to start already in the acute phase after these medical problems occur and ask to pay more attention to these complications throughout the whole chain of recovery and by all involved physicians.
Join the webinar and register now! Duration: 75 minutes Languages: Webinar will be held in English language incl. subtitles if requested and Russian simultaneous translation will be offered.
13th September 2022
